Selexipag
FDA-approved product (tablet, oral), marketed as Selexipag, Uptravi.
- Registered studies
- 41
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Idiopathic and/or familial pulmonary arterial hypertension
- Idiopathic pulmonary arterial hypertension
- Pulmonary arterial hypertension
- Pulmonary hypertension
- Recurrent thrombophlebitis
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Platelet aggregation inhibitors excl. heparin
- FDA pharmacologic class
- Prostacyclin Receptor Agonist FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA45.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli27.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- K. pneumoniae16.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis59.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
41registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Selexipag with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Abiraterone AcetateExisting use: Cancer, Metastatic prostate cancer, Neoplasm and 3 more62.1% AI-predicted activityagainst MRSA50+ registered studies
- TicagrelorExisting use: Acute coronary syndrome, Acute myocardial infarction, Coronary artery disease and 6 more62.1% AI-predicted activityagainst MRSA50+ registered studies
- Edoxaban TosylateExisting use: Atrial fibrillation, Deep vein thrombosis, Pulmonary embolism and 3 more62.1% AI-predicted activityagainst MRSA22 registered studies
- CrizotinibExisting use: Cancer, Neoplasm, Non-small cell lung carcinoma62.0% AI-predicted activityagainst MRSA50+ registered studies
- Montelukast SodiumExisting use: Airway obstruction, Allergic rhinitis, Asthma and 2 more62.0% AI-predicted activityagainst MRSA50+ registered studies
- GrazoprevirExisting use: Chronic hepatitis C virus infection61.9% AI-predicted activityagainst MRSA50+ registered studies
- Octreotide AcetateExisting use: Acromegaly, Carcinoid tumor, Metastasis and 1 more61.7% AI-predicted activityagainst MRSA50+ registered studies
- CyclosporineExisting use: Conjunctivitis, Corneal disease, Eye disease and 6 more61.7% AI-predicted activityagainst MRSA50+ registered studies
- AnidulafunginExisting use: Candidemia, Candidiasis, Peritonitis61.6% AI-predicted activityagainst MRSA43 registered studies
- Triptorelin PamoateExisting use: Central precocious puberty, Metastatic prostate cancer, Neoplasm and 3 more61.6% AI-predicted activityagainst MRSA50+ registered studies
- Vinblastine SulfateExisting use: Classic Hodgkin lymphoma, Fungal infectious disease, Hodgkins lymphoma and 3 more61.5% AI-predicted activityagainst MRSA50+ registered studies
- Lenacapavir SodiumExisting use: HIV infection, HIV-1 infection, Viral disease61.5% AI-predicted activityagainst MRSANo documented evidence found
Registered studies
A registration describes a study; it does not establish a positive result.
Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension
NCT02471183 · start 2015-10-12
Registered record
- Registry ID
- NCT02471183
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Selexipag
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2015-10-12
- Completion
- 2016-12-05
- Enrolment
- 34
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPulmonary Arterial HypertensionInterventionSelexipagPhasePhase 3Registry statusCompletedAbsolute Bioavailability of a Single Oral Dose of Selexipag in Healthy Subjects
NCT02882425 · start 2015-01
Registered record
- Registry ID
- NCT02882425
- Conditions
- Healthy Subjects
- Interventions
- Selexipag for intravenous use; Selexipag for oral use
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2015-01
- Completion
- 2015-04
- Enrolment
- 19
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHealthy SubjectsInterventionSelexipag for intravenous use; Selexipag for oral usePhasePhase 1Registry statusCompletedEffects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis
NCT02260557 · start 2014-10-31
Registered record
- Registry ID
- NCT02260557
- Conditions
- Raynaud's Phenomenon Secondary to Systemic Sclerosis
- Interventions
- Selexipag; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2014-10-31
- Completion
- 2015-06-30
- Enrolment
- 74
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionRaynaud's Phenomenon Secondary to Systemic SclerosisInterventionSelexipag; PlaceboPhasePhase 2Registry statusCompletedStudy in Healthy Male Subjects to Demonstrate Bioequivalence of 1600 μg Selexipag Administered as Eight Tablets of 200 μg or as Single Tablet of 1600 μg
NCT02206295 · start 2012-09
Registered record
- Registry ID
- NCT02206295
- Conditions
- Bioequivalence
- Interventions
- selexipag
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2012-09
- Completion
- 2012-12
- Enrolment
- 80
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionBioequivalenceInterventionselexipagPhasePhase 1Registry statusCompletedStudy of Selexipag and Its Metabolite ACT-333679 on Cardiac Repolarization in Healthy Male and Female Subjects
NCT02206204 · start 2012-06
Registered record
- Registry ID
- NCT02206204
- Conditions
- Cardiodynamics; Safety; Tolerability; Pharmacokinetics
- Interventions
- selexipag; placebo for selexipag; moxifloxacin; moxifloxacin-matching placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2012-06
- Completion
- 2012-11
- Enrolment
- 159
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCardiodynamics; Safety; Tolerability; PharmacokineticsInterventionselexipag; placebo for selexipag; moxifloxacin; moxifloxacin-matching placeboPhasePhase 1Registry statusCompletedPulmonary Arterial Hypertension Quality Enhancement Research Initiative Extension Program
NCT01389206 · start 2011-06-01
Registered record
- Registry ID
- NCT01389206
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- observational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or Uptravi
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Completed
- Start
- 2011-06-01
- Completion
- 2018-04-10
- Enrolment
- 797
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPulmonary Arterial HypertensionInterventionobservational study with patients treated with Tracleer, Ventavis, Veletri, Opsumit and/or UptraviPhaseNot recordedRegistry statusCompletedACT-293987 in Pulmonary Arterial Hypertension
NCT01112306 · start 2010-07-07
Registered record
- Registry ID
- NCT01112306
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- ACT-293987
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2010-07-07
- Completion
- 2021-08-26
- Enrolment
- 709
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPulmonary Arterial HypertensionInterventionACT-293987PhasePhase 3Registry statusCompletedSelexipag (ACT-293987) in Pulmonary Arterial Hypertension
NCT01106014 · start 2009-12-01
Registered record
- Registry ID
- NCT01106014
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Selexipag; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2009-12-01
- Completion
- 2014-10-01
- Enrolment
- 1,156
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPulmonary Arterial HypertensionInterventionSelexipag; PlaceboPhasePhase 3Registry statusCompletedStudy of ACT-293987 (NS-304) in Pulmonary Arterial Hypertension (PAH)
NCT00993408 · start 2008-04-30
Registered record
- Registry ID
- NCT00993408
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- ACT-293987 (NS-304)
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2008-04-30
- Completion
- 2009-06-30
- Enrolment
- 43
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPulmonary Arterial HypertensionInterventionACT-293987 (NS-304)PhasePhase 2Registry statusCompletedCOMPERA / COMPERA-KIDS
NCT01347216 · start 2007-07-01
Registered record
- Registry ID
- NCT01347216
- Conditions
- Pulmonary Arterial Hypertension (PAH); Pulmonary Hypertension (PH)
- Interventions
- Not recorded
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Recruiting
- Start
- 2007-07-01
- Completion
- 2026-12-31
- Enrolment
- 14,000
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionPulmonary Arterial Hypertension (PAH); Pulmonary Hypertension (PH)InterventionNot recordedPhaseNot recordedRegistry statusRecruitingIndividual Patient Expanded Access IND for Selexipag (Uptravi) in Participants With Non-healing Wound, Buerger's Disease
NCT04914247
Registered record
- Registry ID
- NCT04914247
- Conditions
- Non-healing Wound; Thromboangiitis Obliterans
- Interventions
- Selexipag
- Study type
- EXPANDED_ACCESS
- Phase
- Not recorded
- Registry status
- Approved for marketing
- Start
- Not recorded
- Completion
- Not recorded
- Enrolment
- Not recorded
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionNon-healing Wound; Thromboangiitis ObliteransInterventionSelexipagPhaseNot recordedRegistry statusApproved for marketing